You are here

Stanford Accelerated Intelligent Neuromodulation Therapy

Stanford Accelerated Intelligent Neuromodulation Therapy

You’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Stanford Accelerated Intelligent Neuromodulation Therapy

Learning objectives: 

1.     Introduce the concept of interventional psychiatry and the history of therapeutic brain stimulation in psychiatry.

2.     Establish parallels between current approaches in psychiatry with those employed by neurologists, cardiologists, and radiologists. 

3.     Discuss a framework for further development of novel therapeutics for treatment-resistant psychiatric conditions. 


Date of Release: February 7, 2020

Date of Expiration: February 6, 2022

Format: On-Demand

Cost: Due to the cancellation of our November 2020 Grand Round Webinar, this recoding is available to both members and non-members for FREE.

*Please note, this offer does NOT include CME. If you would like to view the recording AND collect CME, please REGISTER HERE

Speaker: Nolan Williams, MD

Dr. Williams is an Assistant Professor within the Department of Psychiatry and Behavioral Sciences and the Director of the Stanford Brain Stimulation Lab. Dr. Williams has a broad background in neuropsychiatry and is double board-certified in both neurology and psychiatry. In addition, he has specific training and clinical expertise in the development of brain stimulation methodologies under Mark George, MD. Themes of his work include (a) examining the use of spaced learning theory in the application of neurostimulation techniques, (b) development and mechanistic understanding of rapid-acting antidepressants, and (c) identifying objective biomarkers that predict neuromodulation responses in treatment-resistant neuropsychiatric conditions. He has published papers in high impact peer-reviewed journals including Brain, American Journal of Psychiatry, and the Proceedings of the National Academy of Science. He has also contributed to two reviews related to novel therapeutics for neuropsychiatric conditions that have been published in the Journal of Clinical Investigation and Current Opinion in Neurobiology, which are both highly cited. Results from his studies have gained widespread attention in journals such as Science and New England Journal of Medicine Journal Watch as well as in the popular press and have been featured in various news sources including Time, Smithsonian, and Newsweek. Dr. Williams received two NARSAD Young Investigator Awards in 2016 and 2018 along with the 2019 Gerald R. Klerman Award. He started the Stanford Brain Stimulation Lab in 2015. He has received several merit-based travel awards to attend and present at the annual meetings for American College of Neuropharmacology, Society of Biological Psychiatry, the American Academy of Neurology and the American Neuropsychiatric Association.

Vertical Tabs

Vertical Tabs

CME is only available to those registered for the webinar at the standard pricing: Members: $25 | Non-members $50 | Student Members FREE

Please CLICK HERE to register. 

Acknowledgement of Financial and/or In-Kind Commercial Support

No financial or in-kind commercial support was received for this educational activity.

Satisfactory Completion 

Learners must complete an evaluation form to receive a certificate of completion. You must participate in the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.   


In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the Clinical TMS Society. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement – Amedco LLC designates this enduring activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco.  All of these relationships were treated as a conflict of interest, and have been resolved.  (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed below.


First Name

Last Name


Commercial Interest:Relationship




CE Coordinator











Halo Neuroscience:Consultant





Takeda Pharmaceuticals:Consultant

Takeda Pharmaceuticals:Scientific/Medical Advisory Board Member

DM Practice Management:Other

Takeda Pharmaceuticals:Speakers Burea

,London TMS Centre:Owner and director

Dyad Medical Ltd:Other


Questions? Email